2026 年 3 月 1 日 行情回顾：上周 A 股医药生物（申万，下同）指数上涨 0.50%，跑输沪深 300 指数 0.58pp，跑输创业板综指 1.82pp，在 31 个子行业中排名第 25。港股恒生 医疗健康指数上周收跌 6.07%，跑输恒生国企指数 4.96pp。 研发进展：上周，康哲药业的 CMS-D008 注射液、康辰药业的 KC1036 片的临 床申请新进承办；海思科的 HSK46575 片、百利天恒的注射用伦康依隆妥单抗 和注射用 BL-M11D1 的 IND 申请新进承办；恒瑞医药的 SHR-1905 注射液以及 SHR-1819 注射液申请临床。 上周，诺诚健华的 ICP-538 以及华润双鹤的 DC6001 正在进行一期临床；复宏 汉霖的 HLX43 和天境生物的普那利单抗进行二期临床；石药集团的 SYH2053 和 SYS6010 进行三期临床；禾元生物的重组人白蛋白（水稻）进行四期临床。 本周观点：坚定看好医药板块回暖，重申投资临床价值三段论 从临床价值三段论看投资主线：1）"0→1"技术突破：创新药领域，高端前沿 创新靶点，正在肿瘤、减重、自免等领域重塑药企研发格局；创新器械领域 ...

Core Insights - Tianjing Biotech successfully completed nearly 600 million RMB in C+ round financing, aimed at advancing phase III clinical trials and market applications for first-tier products, while accelerating the development of second-tier global innovative drug candidates [1] - The financing reflects recognition of Tianjing Biotech's innovative capabilities and growth potential, as well as the strong appeal of the biomedical industry in Hangzhou Qiantang [1] Company Overview - Tianjing Biotech focuses on autoimmune diseases, tumors, and metabolic diseases, and has shown rapid growth since its strategic restructuring in early 2024 [1] - The company has established a diversified revenue model combining commercialization of near-market products, external licensing of innovative products, and CDMO services, effectively balancing high investment and risk in innovation [1] - Key milestones achieved include a strategic cooperation with Sanofi valued at approximately 1.7 billion RMB for the rights of Ureliximab in Greater China, and the breakthrough therapy designation for Punalizumab by the National Medical Products Administration [1] Product Pipeline - The innovative drug pipeline is entering a "harvest period" with a clear "dual-tier" layout, where the first tier includes six major products in late clinical stages, with new drug applications nearing completion [2] - The second tier consists of globally innovative projects and next-generation drugs expected to enter clinical trials between 2025 and 2026 [2] - The production base in Hangzhou plays a crucial role in supporting the entire industry chain, having fully operated its first phase and complied with GMP standards [2] Industry Context - The financing news for Tianjing Biotech is part of a broader trend, as multiple biopharmaceutical companies in Qiantang have also secured funding in the third quarter, indicating a vibrant development ecosystem in the region [3] - Companies like Zhejiang Ganaiwei Medical Technology and Hangzhou Derui Zhiyao Technology have also completed significant financing rounds, showcasing the robust vitality of the Qiantang biomedical industry [3]

Core Viewpoint - Tianjing Biopharma has successfully transformed into a comprehensive, innovative, and commercially broad platform-based biotechnology company, achieving significant milestones since its strategic restructuring in early 2024 [1][2]. Financing and Strategic Partnerships - Tianjing Biopharma completed a C2 round financing of nearly 600 million RMB, led by CICC Capital, with participation from various investment institutions [1]. - The company has established a strategic partnership with Sanofi for the rights to Ureliximab in Greater China, valued at approximately 1.7 billion RMB [1]. - Collaborations with other global and local leaders, such as Boehringer Ingelheim and Shijiazhuang Pharmaceutical, have been initiated to accelerate product development [3]. Product Pipeline and Clinical Development - The company has submitted applications for two products, including Eitan Growth Hormone α and Fizezomab for multiple myeloma indications [1]. - Fizezomab has been recognized as a breakthrough therapy by the National Medical Products Administration and has entered Phase III clinical trials [2]. - The product pipeline is divided into two tiers: the first tier includes six key products nearing commercialization, while the second tier focuses on globally innovative projects with first-in-class potential [2]. Business Model and Revenue Generation - Tianjing Biopharma's diversified revenue model includes commercialization of near-market products, external licensing of innovative products, and CDMO services, effectively balancing R&D investment and risk [1][2]. - The funds raised in the latest financing round will primarily support the Phase III clinical trials and market applications of first-tier products, as well as accelerate the development of second-tier global innovative candidates [2]. Industry Position and Future Outlook - The company is seen as a model of growth potential in the biopharmaceutical industry, particularly in the context of current market challenges and geopolitical changes [2]. - Investors express confidence in Tianjing Biopharma's ability to deliver innovative therapies that meet clinical needs, with a strong focus on autoimmune diseases, metabolic disorders, and oncology [2][3].